The objective of this systematic literature review was to summarize available performance and safety data on topically applied ectoine-containing formulations for the treatment of inflammatory skin diseases in children and adults characterized by an impaired skin barrier.

Six clinical studies were identified through the systematic literature search, including atopic dermatitis and retinoid dermatitis as indications.

Topical formulations with up to 7% ectoine were safe and efficient in pediatric and adult populations when used in long-term application for up to 6 months.

Data suggest that ectoine-containing formulations enhance topical pharmacological therapy in inflammatory skin diseases and, thus, reduced the frequency and/or amount of pharmacological therapy.